ERBB2 and breast carcinoma: Because trastuzumab is now a standard treatment administered to women with HER2 overexpressing breast cancer as part of adjuvant therapy, and because the safety of trastuzumab plus HER2 targeting vaccines has been preliminarily demonstrated [22], future studies will assess the combination of DC-based HER2 targeting vaccines with trastuzumab.